Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 14, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The material change reported is a transfer of 594,566 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on March 10, 2006, and was advised to the Company on March 14, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust for current and former employees, and three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the trust shares similarly to other employees.
Investor Verification Points
- Verify the impact of the 594,566 share transfer on the total outstanding share count.
- Confirm the specific allocation of shares among participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Review the full terms of the GSK Trust to understand the scope of director interests.